<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332024000200078</article-id>
<article-id pub-id-type="doi">10.24875/rccar.m23000224</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La carga económica de la hipertensión arterial en Colombia: un análisis de microcosteo]]></article-title>
<article-title xml:lang="en"><![CDATA[The economic burden of pulmonary arterial hypertension in Colombia: a micro-costing analysis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[Fabián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Larrosa]]></surname>
<given-names><![CDATA[Julieta]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nacazume]]></surname>
<given-names><![CDATA[Jéssica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villaquirán]]></surname>
<given-names><![CDATA[Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conde]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rozo]]></surname>
<given-names><![CDATA[Catalina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco-Watanabe]]></surname>
<given-names><![CDATA[Sarah]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[André]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,IQVIA Colombia IQVIA Colombia ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,IQVIA México IQVIA México ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,IQVIA Brazil IQVIA Brazil ]]></institution>
<addr-line><![CDATA[Sao Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Pontificia Universidad Javeriana Departamento de Neumología y Medicina Interna ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Fundación Neumológica Colombiana Fundación Neumológica Colombiana ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Janssen-Cilag Ltd Janssen-Cilag Ltd ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>78</fpage>
<lpage>84</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332024000200078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332024000200078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332024000200078&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: De acuerdo con el Ministerio de Salud y Protección Social de Colombia, la hipertensión arterial pulmonar (HAP) es una enfermedad huérfana. Aunque existen estudios de costo de la HAP en Colombia, es necesario hacer una actualización del costo de enfermedad.  Materiales y método: Este estudio estimó el costo anual de la HAP en Colombia utilizando metodologías de los manuales de evaluación de tecnologías.  Resultados: Según la consulta a expertos clínicos y líderes de opinión, alrededor del 81% de los pacientes se encontraban en estadio moderado de la enfermedad (FC II y III) y la terapia más frecuente es sildenafilo en monoterapia o combinación. El costo de diagnóstico promedio en Colombia fue de COP $2,904,724.51, mientras que el costo anual de tratamiento promedio asciende a COP $71,410,480. En general, los costos y hospitalizaciones son mayores en etapas avanzadas de la enfermedad.  Conclusiones: Según este estudio, aunque la medicación para el tratamiento de la HAP tiene un alto costo, administrar la terapia adecuada puede mejorar la calidad de vida y reducir la progresión de la enfermedad, las hospitalizaciones y el requerimiento de medicación adicional, lo cual lleva a reducir el costo asociado a la enfermedad. Esto requiere la creación de centros de referencia, y la difusión de información sobre esta patología a los profesionales de la salud.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Pulmonary arterial hypertension (PAH) is an orphan disease according to the Colombian Ministry of Health. Although there is evidence of studies assessing the cost of PAH in Colombia, update of the cost of illness estimation is necessary.  Method: This study´s objective was to estimate the annual cost of PAH in Colombia using the Colombian´s Health Technology Assessment Agency methodology.  Results: Clinical experts and opinion leaders consulted indicated that about 81% of the patients were in a moderate stage of the disease (FC II and III) and that the most frequent therapy is sildenafil in monotherapy or in combination. The average cost of diagnosing the disease in Colombia was US $ $2,088.23(COP $ 2,904,724.51), while the average annual treatment cost amounts to US $51,337.52(COP $71,410,480). Overall, costs and hospital admissions are higher in advanced stages of the disease.  Conclusions: The results of this study indicate that even though drug therapy in PAH is expensive, administering adequate therapy can lead to an improvement in quality of life, a reduction in disease progression, hospitalizations and need for additional medication; reducing costs associated with the disease. This requires the creation of reference centers, and the dissemination of information about this pathology to health care professionals.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión arterial pulmonar]]></kwd>
<kwd lng="es"><![CDATA[Costo de enfermedad]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[Pulmonary arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[Cost of illness]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barst]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ertel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beghetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ivy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary arterial hypertension:a comparison between children and adults]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2011</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>665-77</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simonneau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Montani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Celermajer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Denton]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Gatzoulis]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Krowka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Haemodynamic definitions and updated clinical classification of pulmonary hypertension]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2019</year>
<volume>53</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galiè]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vachiery]]></surname>
<given-names><![CDATA[J-L]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Torbicki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension:the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-119</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Badagliacca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[RMF]]></given-names>
</name>
<name>
<surname><![CDATA[Brida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2023</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2200879</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension:pathophysiology]]></article-title>
<source><![CDATA[European Respiratory Review]]></source>
<year>2010</year>
<volume>19</volume>
<numero>115</numero>
<issue>115</issue>
<page-range>59-63</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miranda-Machado]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Baños-Alvarez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Barrios]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of pulmonary arterial hypertension in the Colombian Caribbean]]></article-title>
<source><![CDATA[Pulmonary Circulation]]></source>
<year>2019</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>2045894019847643</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social - Colombia</collab>
<source><![CDATA[Resolución 0430 de 20132013]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Badesch]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Champion]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez Sanchez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Loyd]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Manes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and assessment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2009</year>
<volume>54</volume>
<numero>1S</numero>
<issue>1S</issue>
<page-range>S55-66</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Blanhir]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona-Rubio]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[de Jesús Rosas-Romero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Márquez]]></surname>
<given-names><![CDATA[GSV]]></given-names>
</name>
<name>
<surname><![CDATA[Arbo-Oze-de-Morvil]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertensión arterial pulmonar, una entidad rara]]></article-title>
<source><![CDATA[Revista de Investigación Clínica i es c i enero-febrero]]></source>
<year>2014</year>
<volume>66</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-78</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galiè]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torbicki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vachiery]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Barbera]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the diagnosis and treatment of pulmonary hypertension]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2009</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1219-63</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boucly]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weatherald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Savale]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jaïs]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Cottin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Prevot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2017</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1700889</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraretti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monaco]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Grazioli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Di Biase]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brunetti]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endothelin-receptor antagonists in the management of pulmonary arterial hypertension:where do we stand?]]></article-title>
<source><![CDATA[Vascular Health and Risk Management]]></source>
<year>2018</year>
<volume>14</volume>
<page-range>253</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phosphodiesterase 5 inhibitors for pulmonary hypertension]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2019</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wardle]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Seager]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wardle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tulloh]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[JSR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guanylate cyclase stimulators for pulmonary hypertension]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2016</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomberg-Maitland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olschewski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostacyclin therapies for the treatment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Eur Resp J]]></source>
<year>2008</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>891-901</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwano]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gatfield]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hamamoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Clozel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selexipag:an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[ACS Publications]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Londoño]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Villaquirán]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dueñas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Coral]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinación de los costos directos e indirectos en hipertensión pulmonar en Colombia]]></article-title>
<source><![CDATA[Rev Colomb Neumol]]></source>
<year>2013</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trow]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The evolving landscape of combination therapy for pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Therapeutic Advances in Respiratory Disease]]></source>
<year>2017</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<collab>Instituto de Evaluación Tecnológica en S</collab>
<source><![CDATA[Manual para la elaboración de evaluaciones económicas en salud]]></source>
<year>2014</year>
<page-range>1-36</page-range><publisher-loc><![CDATA[BogotáD. C ]]></publisher-loc>
<publisher-name><![CDATA[IETS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Instituto de Seguros Sociales</collab>
<source><![CDATA[Manual De Tarifas De La Entidad Promotora De Salud Del Seguro Social &#8220;EPS-ISS&#8221;]]></source>
<year>2001</year>
<page-range>1-208</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coghlan]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early detection and management of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[European Respiratory Review]]></source>
<year>2012</year>
<volume>21</volume>
<numero>126</numero>
<issue>126</issue>
<page-range>306-12</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Londoño]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Claudio Villaquirán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Búsqueda de pacientes con hipertensión pulmonar en el Hospital Universitario San Ignacio]]></article-title>
<source><![CDATA[Rev Colomb Neumol]]></source>
<year>2013</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Celermajer]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early detection of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Nature Reviews Cardiology]]></source>
<year>2015</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-55</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elrod]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Fortenberry]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Centers of excellence in healthcare institutions:what they are and how to assemble them]]></article-title>
<source><![CDATA[BMC health services research]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-24</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
